Back HIV/AIDS

HIV / AIDS

AIDS 2014: Circumcised Men and Female Partners Have Lower Syphilis Rates

A study presented today at the 20th International AIDS Conference in Melbourne found positive associations between voluntary medical male circumcision and reduced incidence of syphilis, not just among men, but also among their female partners. Another study found no evidence of risk compensation among men post-circumcision, while a third used a novel food-voucher scheme as an incentive for getting older men to come forward for circumcision.

alt

AIDS 2014: Mothers Starting Option B+ ART in Malawi Often Lost from Care

Although Malawi’s policy of offering lifelong antiretroviral therapy (ART) to women with HIV who are pregnant or breastfeeding resulted in a 7-fold increase in women receiving treatment in 15 months, implementers are concerned by high rates of loss to follow-up, researchers reported at the 20th International AIDS Conference in Melbourne.

alt

AIDS 2014: Criminalization Decreases HIV Prevention and Treatment Among Gay Men [VIDEO]

Gay and bisexual men who have been arrested or persecuted for same-sex activity are less likely to access HIV prevention services, and those who are HIV positive are less likely to receive antiretroviral treatment, according to a study presented at the 20th International AIDS Conference last month in Melbourne.

alt

FDA Approves ViiV Single-Tablet Regimen Containing Dolutegravir

ViiV Healthcare announced this week that the U.S. Food and Drug Administration (FDA) has approved its all-in-1 antiretroviral fixed-dose combination pill containing the HIV integrase inhibitor dolutegravir (Tivicay) plus abacavir and lamivudine (the drugs in Epzicom or Kivexa). The new coformulation -- with the brand name Triumeq -- is the first single-tablet regimen that does not contain tenofovir and emtricitabine, making it an option for people with impaired kidney function. HLA-B*5701 genetic screening should be done prior to starting Triumeq to test for abacavir hypersensitivity. [Editor's note: On September 3 ViiV announced that the European Commission has also approved Triumeq.]

alt

AIDS 2014: Worldwide Adolescent AIDS Deaths Rising, Especially Among Boys

While new HIV infections have declined among children, adolescents, and adults since 2000, HIV-related deaths have risen sharply among adolescents, especially 15- to 19-year-old males, Tyler Porth of UNICEF reported at the 20th International AIDS Conference last month in Melbourne.

alt

AIDS 2014: Disappointing HIV Cure News Leads to New Questions

The fourth IAS Towards an HIV Cure symposium -- an initiative of the International AIDS Society -- took place July 19-20, prior to the 20th International AIDS Conference in Melbourne.

alt

AIDS 2014: Global ART Demand Projected to Reach 16.8 Million by 2016

The projected demand for antiretroviral therapy (ART) will increase to 16.8 million person-years by the end of 2016 in low- and middle-income countries, including 15.7 million person-years of adult and 1.1 million person-years of pediatric formulations, according to a study presented on behalf of the global ARV Forecasting Technical Working Group at the 20th International AIDS Conference(AIDS 2014) last month in Melbourne.

alt